

SABCS 2023

Los abstracts se pueden visualizar desde la página web del congreso:

<http://www.sabcs.org/FullProgram>

1. Presentaciones de estudios GEICAM

Poster Session 1. December 6. Time: 12:00 PM - 2:00 PM. Halls 2-3.

Presentati on ID	Study code	Abstract Title	Authors
PO1-03-03	ST/2021-02 (STEEP)	STEEP criteria v2.0 validation: A multi-trial analysis using GEICAM and TRIO adjuvant trials to evaluate surrogate endpoints for overall survival.	Lopez Tarruella S, Pollán M, Urruticoechea A, Carrasco E, Spera G, Martín M, Bermejo B, Chap L, Ruíz-Borrego M, Crown J, García-Sáenz JA, Chan A, Guerrero-Zorano A, Bee V, Calvo L, Fresco R, Blasco A, Hernando A, Slamon D
PO1-04-10	ST/2020-01	Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the GEICAM/2013-02 (PEARL) trial	Alva M, López-Tarruella S, Zielinski C, Ruiz-Borrego M, Turner N, Ciruelos E, Muñoz M, Bermejo B, Margeli M, Antón A, Kahan Z, Csösz T, Casas M, Murillo L, Morales S, Alba E, Gal-Yam E, Guerrero-Zotano A, Calvo L, De la Haba-Rodríguez J, Ramos M, Álvarez I, García-Palomo A, Koehler M, García-Sáenz JA, Chacón JI, Swift C, Thallinger C, Gil-Gil M, Martín M
PO1-15-10	TL/2021-08 PEARL	Lower pre-treatment b-cell gene expression signatures correspond with improved overall survival with palbociclib + endocrine therapy in HR+/HER2- metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial	Agrawal N, Fernández-Martínez A, Gil-Gil M, Zielinski C, Ruíz-Borrego M, Ciruelos E M, Muñoz M, Margeli M, Bermejo B, Antón A, Kahan Z, Csösz T, Alonso-Romero JL, García-Sáenz J A, Sánchez-Rovira P, Álvarez E, Chacón J I, González S, Rodríguez C, Servitja S, Pfefferle A, Herranz J, Liu Y, Carey L, Romero-Camarero I, Caballero R, M. Perou C, Martín M
PO1-16-10	GEICAM/2016-04_CANCER_MAMA_VARON	BRCA mutated Male Breast Cancer, hallmarks of a distinct disease. Data from the Spanish Male Breast Cancer Registry (GEICAM/2016-04)	Martínez-Jañez N, Martínez P, Hernando C, Recalde S, Sánchez A, Morales D, Fernández I, Del Barco S, Zamora E, Irazo V, Martos T, Marínez E, Antolín S, Domínguez S, García-Tejido P, Echarri M J, Santaballa A, Mira X, Blasco A, Bezares S, Urruticoechea A
PO1-16-11	GEICAM/2014-03 (RegistEM)	Real-world features and outcomes of young, advanced breast cancer (ABC) patients (pts) from RegistEM (GEICAM/2014-03) study	López-Tarruella S, Guerrero-Zotano A, Álvarez I, Antolín S, Tibau A, Falo C, Cruz J, Rodríguez C, Martínez P, Chacón J I, Hernández M, Margeli M, Adrover E, Gonzalez I, Rodriguez - Lescure A, Marín M, Gómez- Raposo C, De la Haba J, Illarramendi J, Andrés R, Blasco A, Escudero MJ, Bezares S, Rojo F

Poster Session 2. December 6. Time: 5:00 PM - 7:00 PM. Halls 2-3.

Presentation ID	Study code	Abstract Title	Authors
PO2-13-05	GEICAM/2017-07_EMBARCAM	Deciphering pregnancy-associated breast cancer: distinctive molecular profile and clinical implications from GEICAM/2017-07 EMBARCAM study	De la Haba J , Peña R, Pollan M, Jerez-Gilarranz Y, Ponce-Lorenzo J J, Aramburu A, Cantos- Sánchez de Ibarguen B, Santaballa A, Galve-Garre E, Pérez-López M, De la Cruz S, López-Ceballos H, Fernández-Pérez Y, Blancas I, Alonso-Romero J L, Jiménez-Arranz A, Rincón R, Guil S, Díaz-Chacón A, Caballero R, Bermejo B, Guerrero-Zotano A
PO2-19-05	GEICAM/2018-06	Randomized Phase II trial evaluating three anti-diarrhoeal prophylaxis strategies in patients with HER2+ / HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)	Gil Gil M , Martín M, Carrasco E, Galve Calvo E, Martínez Jáñez, González Santiago S, Adamo B, Valero Arbizu M, Martínez Vila C, Guerrero Zotano A, Antolín Novoa S, Ruiz Borrego M, Blancas López-Barajas I, Andrés Conejero R, Alonso Romero JL, Vethencourt Casado A, Chacón López-Muñiz JI, Chavarría Piudo N, Espinosa Arranz E, Hernando Fernández De Aranguiz B, Adrover Cebrián E, Rojo F, Casas M, McCulloch L, Vedovato JC

2. Presentación de estudios en los que participa GEICAM en el listado de autores

ORAL PRESENTATIONS

General Session 1. December 6. Time: 9:00 AM - 12:00 PM. Hall 1

Presentation ID	Study code	Abstract Title	Authors
GS01-03	GEICAM/2017-06 ALEXANDRA/IMpassion030	Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial	Ignatiadis M, Bailey A, McArthur H, El-Abed S, de Azambuja E, Metzger O, Chui S, Dieterich M, Perretti T, Steger G, Jassem J, Chin Lee S, Higgins M, Zarbá J, Schmidt M, Gomez H, Guerrero-Zotano A , Moscetti L, Yang Chiu JW, DuFrane C, Honvault V, Altarcheh R, Molinero L, Ellingson A, Munzone E, Ben-Baruch NE, Bajetta E, Ohno S, Im SA, Werutsky G, Gal-Yam E, Gonzalez-Farré X, Tseng LM, Jacot W, Gluz O, Shao Z, Shparyk Y, Sinielnikov I, Anastasia Z, Vasiliev A, Shearer-Kang E, Winer E, Martins-Branco D, Fielding S, Cameron D, Viale G, Saji S, Gelber R, Piccart M

General Session 2. December 7. Time: 8:15AM-11:15AM. Hall 1.

Presentation ID	Study code	Abstract Title	Authors
GS02-11	GEICAM/2015-05_POSITIVE	Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy	Azim H, Niman S, Partridge A, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal A, Kroep J, Mailliez A, Warner E, Borges V, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J Lee JE, Walshe J, Ruiz - Borrego M , Moore H, Saunders C, Bjelic-Radicic V, Susnjar S, Cardoso F, Klar N, Spanic T, Ruddy K, Piccart M, Korde L, Goldhirsch A, Gelber R, Pagani O, Peccatori FA

General Session 3. December 8. Time: 8:15AM-11:15AM. Hall 1.

Presentation ID	Study code	Abstract Title	Authors
GS03-03	GEICAM/2018-04_TRIO033_NATALEE	Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial	Hortobagyi G, Stroyakovsky D, Yardley D, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martín M , Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroosse R, Visco F, Parnizari F, Ghaznawi F, Li Z, Waters S, Chakravarty A, Slamon D

GS03-07	GEICAM/2014-07 PALLAS	Protocol-defined biomarker analysis in the PALLAS adjuvant trial: genomic subtype derived from RNA sequencing of HR+/HER2- eBC	Stover D, Hlascsek D, Mayer E, Symmans WF, Watson M, Barozzi I, Filipits M, Ballman K, Bellet- Ezquerro M, Balko J, Rubovszky G, Zdenkowski N, Brufsky A, Steger G, Isaacs C, Loibl S, Henao F , Regan M, Liu Y, Fesl C, O'Brien P, DeMichele A, Gnant M, Metzger O
----------------	----------------------------------	--	--

Late Breaking Abstracts Oral Session. December 8. Time: 12:00 PM-12:45 PM. Star at Night Ballroom 1-2

Presentation ID	Study code	Abstract Title	Authors
LBO1-02	GEICAM/2017-05 APTneo	Pathologic complete response (pCR) of neoadjuvant therapy with or without atezolizumab in HER2-positive, early high-risk and locally advanced breast cancer: APTneo Michelangelo randomized trial	Gianni L, Munzone E, Mansutti M, Bianchini G, Izaruzaga Y, Rota Caremoli E, Dirix L, Del Mastro L, González-Santiago S , Schneeweiss A, Ponce J, Huang CS, Wimberger P, Altintas S, Martín M , Antone N, Singer CF, De Giorgi U, Godoy Ortiz A, Lueck HJ, Spezia R, Fasolo A, Viale G, Valagussa P

POSTER DISCUSSION

Spotlight Discussion session. "Biomarkers of response and/or resistance to endocrine based therapies: Implications for treatment approaches"

December 8. Time: 7:00 AM - 8:00 AM. Hemisfair Ballroom 1-2.

Presentation ID	Study code	Abstract Title	Authors
PS17-04	GEICAM/2014-11_AURORA	Clinical and Genomic Features of ER-Positive/HER2-negative Metastatic Breast Cancer in AURORA Molecular Screening Initiative (BIG 14-01): Mechanisms of Endocrine Therapy Resistance and Implications for Adjuvant Approaches	Guerrero-Zotano A , Benelli M, Irrthum A, Cameron D, Ferrando L, Romagnoli D, Paoli M, Llinas A, Dadiani M, Fimereli D, Oliveira M, Caballero C, Crestani T, Agostinetto E, Martins-Branco D, Hilbers F, Gal-Yam E, Balic M, Cardoso F, Reis-Filho J, Sotiriou C, Curigliano G, Linderholm B, de Azambuja E, Knox S, Rotaru C, Ciruelos E, Davidson NE, Viale G, Taylor D, Canon JL, Calvo L, Albanell J, Colleoni M, Duhem C, Harbeck N, Herremans C, Loibl S, Marreaud S, Scheepers E, Raimbault A, Goulioti T, Vingiani A, Biagioni C, Vosberg S, Zoppoli G, Seoane J, Venet D, Aftimos P, Piccart M

POSTER PRESENTATION

Poster Session 1. Wednesday, December 6. Time: 12:00-2:00PM. Halls 2-3.

Presentation ID	Study code	Abstract Title	Authors
PO1-01-08	GEICAM/2014-07 PALLAS	The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with HR+/HER2- eBC: an exploratory analysis of the PALLAS study	Agostinetto E, Pfeiler G, Hlauschek D, Mayer E, Lambertini M, de Azambuja E, Bellet-Ezquerria M, Meisel J, Rubovszky G, Zdenkowski N, Novik Y, Ruiz - Borrego M , Gelmon K, Mamounas E, Iwata H, Lu D, Sölkner L, Fesl C, Gnant M, DeMichele A
PO1-01-13	GEICAM/2014-07 PALLAS	Clinical characterization, prognosis and predictive values of HER2-low in eBC in the PALLAS trial	Nader-Marta G, Singer CF, Hlauschek D, DeMichele A, Tarantino P, Pfeiler G, Martín M , Balko J, Nowecki Z, Balic M, Brufsky A, Chan A, Morris PG, Haddad T, Loibl S, Liu Y, Sölkner L, Fesl C, Mayer E, Gnant M

Poster Session 4. Thursday December 7. Time: 5:00 PM - 7:00 PM. Halls 2-3

Presentation ID	Study code	Abstract Title	Authors
PO4-02-04	GEICAM/2013-03_PENELOPEB	Overall survival and disease recurrence rates in patients with invasive lobular breast cancer of the PenelopeB cohort	Bonnefoi H, Marmé F, Martín M , Untch M, Kim SB, Bear H, McCarthy N, Gelmon K, García-Sáenz JA , Kelly CM, Reimer T, Zhang Z, Toi M, Rugo H, Gnant M, Makris A, Hirmas N, Nekljudova V, Holtschmidt J, Loibl S
PO4-18-01	na	International Validation of a Staging Model for de novo Metastatic Breast Cancer	Plichta J, Thomas S, Siesling S, de Munck L, Lusque A, Grinda T, Gondara L, Chia S, Cabrera-Galeana P, Reynoso-Noverón N, López-Tarruella S , Álvarez López I , Edge S, Hortobagyi G

na: no aplica

3. Presentación de estudios en los que participa GEICAM (sin autoría)

**Poster Spotlight Sessions Block 3. “Exploiting Tumor Biology in HER2-positive Breast Cancer to Escalate or De-escalate Neoadjuvant Therapy”.
December 6. Time: 5:30 PM-6:30PM. Stars at Night Ballroom 1-2**

Presentation ID	Study code	Abstract Title	Authors
PS09-04	GEICAM/2010-11_APHINITY	The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: sub-analysis of the APHINITY trial	de Azambuja E, Agostinetto E, Samy F, Di Cosimo S, Aftimos P, Pondé N, Eiger D, Lambertini M, Cameron D, Kiermaier A, Bailey A, Viale G, Loi S, Piccart M

Poster Session 3. December 7. Time: 12:00 PM - 2:00 PM. Halls 2-3.

Presentation ID	Study code	Abstract Title	Authors
PO3-02-05	GEICAM/2014-07 PALLAS	Racial and ethnic differences in clinical outcomes among north american patients with HR+/HER2-, eBC in the PALLAS trial	Kantor O, Fayanju O, Dueck A, Gnant M, Burstein H, Goetz M, Isaacs C, Shepherd L, Hahn O, Anderson D, Miller K, Rugo H, Traina T, Dayao Z, Clifton K, Winer E, Wolff A, Wolmark N, Lu D, O'Brien P, Scovil S, DeMichele A, Mayer E